Romanski S A, McCarthy J T, Kluge K, Fitzpatrick L A
Bone Histomorphometry Laboratory, Mayo Clinic Rochester, MN 55905.
Mayo Clin Proc. 1993 May;68(5):419-26. doi: 10.1016/s0025-6196(12)60186-4.
We compared the sensitivity of aurin tricarboxylic acid (ATA) or acid solochrome azurine (ASA) for detecting bone aluminum histochemically in 87 biopsy specimens obtained between 1983 and 1987 from 84 patients receiving dialysis therapy. Two consecutive biopsy sections were stained, one with ATA and the other with ASA, and then interpreted independently by two experienced observers. Three groups were established: group 1 (N = 61) had positive results of both ATA and ASA staining, group 2 (N = 25) had negative ATA but positive ASA sections, and group 3 (N = 1) had negative results of both ATA and ASA. No significant differences existed between groups 1 and 2 for age of the patients or serum calcium or immunoreactive parathyroid hormone levels. Patients in group 1 had significantly higher bone aluminium content (110 versus 61 micrograms/g dry ash weight), higher serum aluminum levels (151 versus 26 ng/ml), and longer duration of dialysis (85 versus 30 months) than did patients in group 2. Bone biopsy diagnoses (group 1 versus group 2) included low-turnover bone disease, 8 versus 7; osteomalacia, 26 versus 0; mixed uremic bone disease, 10 versus 1; hyperparathyroidism, 12 versus 14; and mild uremic bone disease, 5 versus 4. On the basis of ATA staining, 7 of 15 patients with low-turnover and 1 of 11 patients with mixed uremic bone disease may have been incorrectly diagnosed as having non-aluminum-related bone disorders. The levels of bone and serum aluminum were lower in group 2 than in group 1 but still much higher than normal.(ABSTRACT TRUNCATED AT 250 WORDS)
我们比较了金精三羧酸(ATA)或酸性溶剂蓝(ASA)在组织化学上检测87份活检标本中骨铝的敏感性,这些标本于1983年至1987年间取自84例接受透析治疗的患者。连续的两个活检切片分别用ATA和ASA染色,然后由两名经验丰富的观察者独立解读。分为三组:第1组(N = 61)ATA和ASA染色结果均为阳性,第2组(N = 25)ATA切片阴性但ASA切片阳性,第3组(N = 1)ATA和ASA结果均为阴性。第1组和第2组患者在年龄、血清钙或免疫反应性甲状旁腺激素水平方面无显著差异。与第2组患者相比,第1组患者的骨铝含量显著更高(分别为110微克/克干灰重和61微克/克干灰重)、血清铝水平更高(分别为151纳克/毫升和26纳克/毫升)以及透析时间更长(分别为85个月和30个月)。骨活检诊断(第1组与第2组)包括低转换骨病,分别为8例和7例;骨软化症,分别为26例和0例;混合性尿毒症骨病,分别为10例和1例;甲状旁腺功能亢进,分别为12例和14例;以及轻度尿毒症骨病,分别为5例和4例。基于ATA染色,15例低转换患者中有7例以及11例混合性尿毒症骨病患者中有1例可能被错误诊断为非铝相关性骨病。第2组的骨铝和血清铝水平低于第1组,但仍远高于正常水平。(摘要截短至250字)